Clovis Oncology Stock Boosted By Promising Regulatory Update

A short squeeze could push CLVS even higher

Managing Editor
Feb 22, 2018 at 10:25 AM
facebook twitter linkedin


Clovis Oncology Inc (NASDAQ:CLVS) stock is up 7.4% to trade at $59 this morning, after the company received a positive trend vote from a European Union (EU) committee for its ovarian cancer drug marketing application. In response, RBC upgraded CLVS stock to "outperform" from "sector perform," while cutting its price target to $72 from $80. The analyst in coverage is calling for a positive outcome when the official vote is taken next month, and predicts a strong launch for the treatment in the U.S. during the second quarter.

Clovis stock is on track for its best day in months, but is struggling to overcome the 50-day moving average that's contained the past two breakout attempts. The equity is also trading right near its year-over-year breakeven level as it tries to recover the losses it's suffered since peaking just below the century level back in July.

A short-squeeze that could provide tailwinds for the security. Short interest increased by 6% during the last reporting periods, and accounts for nearly 17% of CLVS's total available float. This represents nearly one week of pent-up buying demand.

Whether you're expecting a pullback or extended upside, it's a good time to speculate on CLVS with short-term options. That is, the stock has a Schaeffer's Volatility Index (SVI) of 58%, which sits just 12 percentage points from a 52-week low, hinting at lower-than-usual volatility expectations for near-term contracts. This is especially surprising since the company is slated to report earnings after the close on Monday.

Make the Most of the next Expiration Week Countdown!


 




 
Special Offers from Schaeffer's Trading Partners